Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

APR-2020

Phase 1Biologic

AApriligen, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

RPS19 Deficient Diamond-Blackfan AnemiaRecruiting

RPS19 Deficient Diamond-Blackfan AnemiaPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

RPS19 Deficient Diamond-Blackfan Anemia

NCT07476183

Clinical

Trials by Indication[1]

RPS19 Deficient Diamond-Blackfan Anemia1 trial

A Phase 1, Open-label, Single-arm Study of APR 2020 in Transfusion Dependent, Steroid Resistant Pediatric and Adolescent Subjects With RPS19 Deficient Diamond Blackfan Anemia by Transplantation of Autologous CD34+ Stem Cells Transduced With CLIN LV EFS coRPS19 PRE* (APR-2020)

Recruiting·AApriligen, Inc.·Phase 1·NCT07476183·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for APR-2020. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APR-2020 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APR-2020. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Apriligen, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: AApriligen, Inc.

Related News